Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has started a phase I trial to study the safety and tolerability of PRX-07034, a once-daily treatment for obesity.
Subscribe to our email newsletter
PRX-07034 is a highly selective 5-HT6 receptor antagonist being developed for the treatment of obesity, as well as for cognitive impairment associated with Alzheimer's disease and schizophrenia.
“We recently completed a single dose study of PRX-07034 and results from that trial demonstrated that PRX-07034 was well tolerated and supported once-daily oral dosing,” said Michael Kauffman, CEO of EPIX Pharmaceuticals.
Preliminary safety and tolerability data from the recently completed single dose phase I trial indicated that single doses of PRX-07034 were well tolerated up to the highest dose tested. In addition, PRX-07034 demonstrated adequate absorption, making it suitable for once daily dosing.
PRX-07034 has also shown cognitive enhancing properties in preclinical animal models of memory impairment, as well as reductions of both food intake and body weight in several preclinical animal models of obesity.